Nurexone Biologic Inc
F:J90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bank of India Ltd
NSE:BANKINDIA
|
IN |
|
TRE Holdings Corp
TSE:9247
|
JP |
Nurexone Biologic Inc
Common Stock
Nurexone Biologic Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Enerflex Ltd
TSX:EFX
|
Common Stock
CA$498m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Common Stock
CA$564m
|
CAGR 3-Years
55%
|
CAGR 5-Years
31%
|
CAGR 10-Years
15%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Common Stock
CA$372m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-3%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Common Stock
CA$595m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-4%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Common Stock
$31.3m
|
CAGR 3-Years
45%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
